Moderna (MRNA) Net Cash Flow Growth (1y) (2019 - 2026)
Moderna (MRNA) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 53.46% |
| 10 | Moderna | 21.91 Bn | 16.70 Bn | -566.00 Mn | -127.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -127.39% |
| Dec 31, 2025 | 416.96% |
| Sep 30, 2025 | 82.25% |
| Jun 30, 2025 | -184.60% |
| Mar 31, 2025 | 64.64% |
| Dec 31, 2024 | 1,232.00% |
| Sep 30, 2024 | 4.03% |
| Jun 30, 2024 | 13.30% |
| Mar 31, 2024 | -451.23% |
| Dec 31, 2023 | -114.20% |
| Sep 30, 2023 | -657.05% |
| Jun 30, 2023 | 116.60% |
| Mar 31, 2023 | 113.56% |
| Dec 31, 2022 | -86.45% |
| Sep 30, 2022 | 394.34% |
| Jun 30, 2022 | -1,450.93% |
| Mar 31, 2022 | -163.90% |
| Dec 31, 2021 | 16.19% |
| Sep 30, 2021 | 79.30% |
| Jun 30, 2021 | -88.25% |